Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $206.48 and traded as high as $211.09. Genmab A/S shares last traded at $211.09, with a volume of 330 shares.
Genmab A/S Stock Performance
The firm's 50 day simple moving average is $207.69 and its 200 day simple moving average is $205.76. The firm has a market cap of $13.95 billion, a PE ratio of 11.97 and a beta of 0.92.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $3.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The company had revenue of $765.14 million for the quarter, compared to analyst estimates of $761.09 million. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
